We utilized database analysis, cancer cell assays and PDX models and revealed that SYK stratification consistently enriched the population of patients predicted to be responsive to EGFRis and ALKis among those with EGFR-mutant and ALK-translocated NSCLC, respectively. The gene discussed is EGFR; the disease is cancer.